The downstream effector of the HIPPO pathway, TAZ, is expressed in ovarian cancers without ARID1A indicating that TAZ inhibitors could be used to induce synthetic lethality or an agonist that promotes ARID1A expression. Here, ARID1A is linked to ovarian carcinoma.